Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

N/AUnknownNCT03311984

Southeast University, China200 enrolled

Overview

Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threatening embolism. The purpose of this study is to evaluate the anti-Xa levels of different dosing regimens of LMWH in critically ill patients in China.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Critically Ill Anti-Xa

Interventions

anti Xa levelDIAGNOSTIC_TEST

monitoring the anti-Xa level according to LMWH emploing

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult Critically ill patients Exclusion Criteria: * Contraindication to use of LMWH. Intracranial bleeding/stroke, hematoma or bleeding disorder. Use Heparin anticoagulant therapy

Locations (1)

Changde Wu

Nanjing, Jiangsu, China

Outcomes

Primary Outcomes

Anti-Xa Levels

Time frame: six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.